Since BTKi resistance following chronic exposure to acalabrutinib or ibrutinib resulted in increased expression of 14q32 cluster miRNAs and lower levels of PTEN, we examined the effects of acute acalabrutinib and ibrutinib treatment on 14q32 cluster miRNAs in BTKi-sensitive ABC-DLBCL and CLL cells. This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.